Travere Therapeutics, Inc. is a biopharmaceutical company, which engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
497
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Travere Therapeutics Inc market cap is $4.51B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Travere Therapeutics Inc 52 week high is $68.73 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Travere Therapeutics Inc 52 week low is $22.59 as of November 22, 2026.
Travere Therapeutics Inc stock price today is $47.00.
Travere Therapeutics Inc stock price yesterday was $48.30.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Travere Therapeutics Inc's P/E ratio is -28.33.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Travere Therapeutics Inc P/B ratio is 199.1104.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Travere Therapeutics Inc 50-day moving average is $54.23.